Jessie Anderson’s Post

🙏🏼 A very big #ThankYou to everyone who attended #GenAI4Pharma: #London last week; especially to all the speakers, panelists, startups and, of course, our event partners: Slalom, Amazon Web Services (AWS) and Coulter Partners. ⭐️ On May 14th, I had the pleasure of hosting the 3rd installment of my global series of #GenAI4Pharma events in London (UK). We had a wonderful turnout of almost 100 attendees, filling the lovely Slalom offices to capacity, leaving standing room only. 🎤 The day kicked off with Richard Fayers, who welcomed us to Slalom's London Bridge office. He also shared Slalom's perspective on "Navigating AI Strategies" and why it's important to go beyond just using #AI for #productivity or efficiency gains, but to also consider how it can forge uniqueness through #differentiation and ultimately lead revolutionary change through #disruption. 🧊 Subsequently, we had a hands-on #GenAI icebreaker, led by my brilliant and creative friend, Henry Coutinho-Mason, who took us through an artful journey to demonstrate how GenAI can help anyone level-up — even for things that we aren't very skilled at. For example, not everyone is good at drawing/art, but we all gave it a go and we were able to transform some basic/novice sketches into meaningful and professional outputs through the help of #GenAI! ✨ If you're interested in this, please reach out to Henry or myself — we've incorporated it into our #FutureNormal #CorporateInnovation workshop that we collaborate on. 🔑🎵 We then kicked off our keynote sessions with three insightful and enlightening discussions, including: 1️⃣ "#DeepLearning in #DrugDiscovery" — a presentation by Sarah Skerratt, FRSC (CSO of CHARM Therapeutics) on how #DragonFold — a #FoundationModel for predicting protein-ligand interactions — can help accelerate R&D for "#undruggable targets". 2️⃣ A "#GenAI — An Investment Opportunity" panel, moderated by Alex Merwin, along with: Natalie Pankova, Leigh Brody and Ala Alenazi. They discussed a focus on impact and outcomes for any technology, as well as the importance of cultivating talent. 3️⃣ A "#GenAI in Pharma" panel, moderated by Richard Butler, together with Julie Huxley-Jones, Leonard Wossnig and Sarah Skerratt, FRSC. They talked about how #DataQuality and #TrustedAlgorithms were two important criteria to overcome the big challenges in the pharma race for: targets, molecules, clinical trials and launch. 🏁 Finally, we had 6 great startups pitch their #pharma-focused #GenAI platforms: ► cfdx — a precision #neuroscience startup using #AI to develop a synthetic brain biopsy. ► Conduit Bio — a data refinery and AI engine for #DrugDiscovery ► DeepMirror — a #GenAI-powered drug design platform ► Lindus Health — an "anti-CRO" applying #AI to #TrialDesign, #PatientRecruitment and #DataManagement ► Sinkove — a #GenAI-powered biomedical imaging platform ► Tehistark — accelerating clinical/regulatory dossier generation with #AI

Congratulations to the following Lightspeed-backed companies on their recent funding announcements: → Wiz, a Cloud Security Platform helping hundreds of the world's leading and fastest-growing organizations rapidly identify and remove critical risks in cloud environments. cc: Co-Founders Yinon C., Assaf Rappaport, Ami Luttwak, and Roy Reznik. → Suno, a generative artificial intelligence music creation program building a future where anyone can make great music. cc: Co-Founders Mikey Shulman Georg Kucsko, Martin Camacho, and Keenan Freyberg → Pheon Therapeutics, a leading Antibody-Drug Conjugate (ADC) specialist developing next-generation ADCs for a wide range of hard-to-treat cancers. cc: President & CEO Cyrus Mozayeni and Co-Founder Paul Jackson → Patronus AI, the first automated evaluation and security platform that helps companies detect large language model (LLM) mistakes at scale. cc: Co-Founders Anand Kannappan and Rebecca Qian Swipe to find out more about their missions and visions.

"The cure for cancer is likely to come from a Compute Cluster in the cloud" is something I've been intentional about saying in almost every talk I've given over the past 5+ years. We're getting closer... I'm honored to be the Executive Sponsor for EvolutionaryScale, a #Startup who launched their cutting-edge ESM3 model for researchers and scientists - and it’s now available on Amazon Web Services (AWS). ESM3 has the remarkable ability to generate entirely new proteins that have never existed before, allowing for “programmable biology.” Models like ESM3 have the potential to significantly speed drug discovery timelines and lower costs. This is how we accelerate innovation on our shared journey to solve the world's biggest challenges - and we are going to continue making it easier for scientists everywhere to use #GenAI for drug discovery and development. Alex Rives Tom Sercu Dan Sheeran (he/him) Josh Wolfe Nat Friedman AWS Startups Brennan Demro Greg Pearson Kellen O'Connor Matt Garman Swami Sivasubramanian Matt Wood Baskar Sridharan https://lnkd.in/gsCJ_Wx9

We are excited to introduce the four companies we have accepted into Wharton Cypher Accelerator, Eoliann, Pocket Scribe, MediMint, and pre.dev. #CypherAccelerator #DominionCohort The Wharton School Eoliann is a climate tech startup that leverages satellite data and artificial intelligence to forecast the probability, intensity, and impact of climate events. Roberto Carnicelli, 💻 Chiara Mugnai, Giovanni Luddeni, Emidio Granito Pocket Scribe is a documentation and revenue enhancement tool for clinicians to tackle burnout and declining reimbursement rates from billing changes. Nikhil Illa, MD, Jennifer Rooney, MS, Patrick Emery MediMint is the first entirely blockchain-powered platform for providers and patients that seamlessly facilitates the sharing of medical image studies, paving the way for a new era of patient-centered healthcare. Abhisri Ramesh, Ava R., Kelly L., Dr. Berndt Schmit, MD MBOE pre.dev integrates seamlessly with popular PM tools to bring project plans to life and provides access to rapid development through a network of engineers. Arjun Raj Jain, Adam Elkassas 

#FounderSpotlight Today, we want to highlight Dr. Armstrong Murira and Dr. Nardin Nakhla, the dynamic duo behind Simmunome Inc. - an artificial intelligence-powered startup focused on predicting the likelihood of drug candidates to fail (or succeed) in clinical trials. Through this they help their clients discover the right pathway to go after in disease treatment; reducing the cost and time spent on clinical trials on one hand, and increasing their efficiency and success rate on the other. Dr. Armstrong Murira (Co-founder & CEO) received his Ph.D. in Biochemistry and Molecular Biology from Simon Fraser University, where he also majored in Bachelor’s of Business Administration. His research focused on leveraging computational biology to understand human biological networks that cause and fight disease. In 2016, he developed the idea for Simmunome during his post-doc, where he connected with Dr. Nardin Nakhla through a mutual friend. Dr. Murira’s technical and business background allows him to handle the business and sales aspects of the company. As the co-founder and CTO of Simmunome Inc., Dr. Nardin Nakhla combines her knowledge in engineering, machine learning, and neuroscience to lead the company's research and development efforts, focusing on innovative AI models that simulate disease pathways and predict drug efficacy outcomes. After gaining experience as a regional electrical engineer at Procter & Gamble, Nardin's passion for research drew her back to academia. This led her to pursue a Ph.D. in Neuroscience at McGill University, where she utilized machine learning and diverse modeling techniques to investigate the brain's information processing and learning capabilities. Simmunome was born out of their combined passion for finding new ways to understand and treat complex diseases. At BKR Capital, we are dedicated to unearthing and supporting Canada’s most promising founders who are disrupting industries based on a combination of clear market understanding and sound technical expertise. #BKRCapital #BKRCapitalPortco #VentureCapital #BlackEntrepreneurs #BlackInTech #BlackExcellence #innovation #TechStartups

Looking forward to participating in this conversation on Biotech, Healthcare and AI! Thanks to Bernstein for hosting!

Will the life sciences dethrone software as the king of technology? The life science sector has been capturing more venture capital, employing more people and reshaping innovation economies across the US. And we’ve got the data to back it up. https://lnkd.in/gS_b-tpa #VC #LifeSciences #Software #TechInvestments

The second cohort for lablab NEXT is launching at the end of October! This 6-week digital program for early #AI startups, provides hands-on support, a personalized roadmap, and access to a 165K+ AI community plus tech stack credits from global top providers. Here are the nine #startups that are part of our current program: AUTODERM: Get quicker skin diagnosis on your phone, reducing wait times by 70%. Orbit8: AI career advisor connecting students, teachers, and employers. Maia Genomics: Rapid DNA analysis for actionable health insights. Perlon AI: 10x faster AI-powered email generation for better sales. Smabbler: Build more reliable AI and next-gen RAG with automated graph annotations. MindGraph: 90% improved document search and project mapping for construction. ShiftLeft AI.ai: AI-driven software testing for efficient system integration. Brihaspati AI: Real-time AI astrology for stress relief. AIPTO: AI-enhanced lab tests for personalized cancer treatment plans. Apply here : https://lnkd.in/dtsvc7hj

Exciting News from Sygnomics! We are thrilled to announce that Sygnomics has successfully graduated from the Creative Destruction Lab (CDL) Seattle accelerator program!  After an intense nine-month journey at CDL-Seattle, hosted by the University of Washington and supported by innovators like Microsoft, we have honed our mission of transforming oncology through personalized medicine. Our team worked diligently alongside more than 70 mentors, including some of the brightest minds from the Pacific Northwest, to meet rigorous, objective-based milestones. CDL-Seattle is unique as it empowers startups without taking equity, focusing on propelling forward-thinking companies toward real-world impact. From nearly 300 initial applications to the final 17, Sygnomics has proven its commitment and capability in advancing personalized oncology solutions that predict patient risk with greater accuracy. As we celebrate this milestone, we extend our deepest gratitude to the CDL community, our fellow cohort members, and everyone who has supported us on this path. The journey doesn't end here; it's just the beginning of our commitment to revolutionizing patient care through cutting-edge technology and research. Stay tuned for more updates as we continue to grow and push the boundaries of computational health. Here's to making a significant impact on how healthcare is delivered and experienced! Startups that graduated from CDL were highlighted in the GeekWire this week. https://lnkd.in/g3sQrZyT #CDLGraduation #Innovation #StartupLife #Oncology #PersonalizedMedicine #Sygnomics #HealthTech #ThankYou #CDL

Yesterday we announced Briefly's fundraise and our aim to tackle scientific reproducibility. I wanted to break down our thoughts on reproducibility a little, since that word (understandably!) comes with a lot of baggage. In doing so I hope you'll get a better idea of why we think this company should exist, and why now is the right time to start it. Give it a read below 👇 https://lnkd.in/eJSYw7Dx